We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Denies Pfizer Petition Asking for New Method of Assessing Premarin Generics
FDA Denies Pfizer Petition Asking for New Method of Assessing Premarin Generics
The FDA has denied a citizen petition from Pfizer calling on the agency to use the company’s method for assessing sameness in generics for its estrogen drug Premarin (conjugated estrogens).